Cargando…

OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF-β type I receptor

Ovo-like transcriptional repressor 1 (OVOL1) is a key mediator of epithelial lineage determination and mesenchymal–epithelial transition (MET). The cytokines transforming growth factor-β (TGF-β) and bone morphogenetic proteins (BMP) control the epithelial–mesenchymal plasticity (EMP) of cancer cells...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Chuannan, Wang, Qian, van der Zon, Gerard, Ren, Jiang, Agaser, Cedrick, Slieker, Roderick C., Iyengar, Prasanna Vasudevan, Mei, Hailiang, ten Dijke, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050647/ https://www.ncbi.nlm.nih.gov/pubmed/35484112 http://dx.doi.org/10.1038/s41392-022-00944-w

Ejemplares similares

ST3GAL5‐catalyzed gangliosides inhibit TGF‐β‐induced epithelial‐mesenchymal transition via TβRI degradation
por: Zhang, Jing, et al.
Publicado: (2022)

LncRNA LITATS1 suppresses TGF‐β‐induced EMT and cancer cell plasticity by potentiating TβRI degradation
por: Fan, Chuannan, et al.
Publicado: (2023)

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression
por: Sinha, Abhishek, et al.
Publicado: (2021)

Epigenetic Reprogramming of TGF-β Signaling in Breast Cancer
por: Suriyamurthy, Sudha, et al.
Publicado: (2019)

Regulation of Ubiquitin Enzymes in the TGF-β Pathway
por: Iyengar, Prasanna Vasudevan
Publicado: (2017)

TGF-β Signaling in Breast Cancer Cell Invasion and Bone Metastasis
por: Drabsch, Yvette, et al.
Publicado: (2011)

Transcription Factors OVOL1 and OVOL2 Induce the Mesenchymal to Epithelial Transition in Human Cancer
por: Roca, Hernan, et al.
Publicado: (2013)

VprBP mitigates TGF-β and Activin signaling by promoting Smurf1-mediated type I receptor degradation
por: Li, Yihao, et al.
Publicado: (2019)

OVOL2 in metastasis prevention in NPC
por: Song, Kyung-A, et al.
Publicado: (2018)

OVOL2 antagonizes TGF-β signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis
por: Wu, Rong-Si, et al.
Publicado: (2017)

TGF-β-Induced Endothelial to Mesenchymal Transition Is Determined by a Balance Between SNAIL and ID Factors
por: Ma, Jin, et al.
Publicado: (2021)

Targeting TGFβ signal transduction for cancer therapy
por: Liu, Sijia, et al.
Publicado: (2021)

OVOL guides the epithelial-hybrid-mesenchymal transition
por: Jia, Dongya, et al.
Publicado: (2015)

TGFβ Signaling and Cardiovascular Diseases
por: Pardali, Evangelia, et al.
Publicado: (2012)

TGF-β in progression of liver disease
por: Dooley, Steven, et al.
Publicado: (2011)

Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer
por: Zhang, Xiujuan, et al.
Publicado: (2022)

OVOL1 Influences the Determination and Expansion of iPSC Reprogramming Intermediates
por: Kagawa, Harunobu, et al.
Publicado: (2019)

Regulation of endothelial cell plasticity by TGF-β
por: van Meeteren, Laurens A., et al.
Publicado: (2011)

Bone morphogenetic protein receptor signal transduction in human disease
por: Gomez‐Puerto, Maria Catalina, et al.
Publicado: (2018)

TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling
por: Iyengar, Prasanna Vasudevan, et al.
Publicado: (2022)

TGF‐β signaling in liver metastasis
por: Marvin, Dieuwke L, et al.
Publicado: (2020)

OVOL2 sustains postnatal thymic epithelial cell identity
por: Zhong, Xue, et al.
Publicado: (2023)

Editorial: TGF-β and BMP signaling in cancer
por: Yan, Xiaohua, et al.
Publicado: (2022)

Key role for ubiquitin protein modification in TGFβ signal transduction
por: De Boeck, Miriam, et al.
Publicado: (2012)

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis
por: Hao, Yang, et al.
Publicado: (2019)

Age-dependent alteration of TGF-β signalling in osteoarthritis
por: van der Kraan, Peter M., et al.
Publicado: (2011)

OTUD4 enhances TGFβ signalling through regulation of the TGFβ receptor complex
por: Jaynes, Patrick William, et al.
Publicado: (2020)

Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of OVOLs in Breast Cancer
por: Chen, Jingsheng, et al.
Publicado: (2021)

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
por: Huynh, Linh Khanh, et al.
Publicado: (2019)

The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed PMP22
por: Michailidou, Iliana, et al.
Publicado: (2023)

Cercosporamide inhibits bone morphogenetic protein receptor type I kinase activity in zebrafish
por: Hoeksma, Jelmer, et al.
Publicado: (2020)

Role of glycosylation in TGF-β signaling and epithelial-to-mesenchymal transition in cancer
por: Zhang, Jing, et al.
Publicado: (2020)

Ovol2, a zinc finger transcription factor, is dispensable for spermatogenesis in mice
por: Zhang, Jin, et al.
Publicado: (2019)

JUNB governs a feed-forward network of TGFβ signaling that aggravates breast cancer invasion
por: Sundqvist, Anders, et al.
Publicado: (2018)

Low Transforming Growth Factor-β Pathway Activity in Cervical Adenocarcinomas
por: Marvin, Dieuwke L., et al.
Publicado: (2022)

TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases
por: Pardali, Evangelia, et al.
Publicado: (2017)

Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models
por: Sow, Heng Sheng, et al.
Publicado: (2019)

TGF-β-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering
por: Ma, Jin, et al.
Publicado: (2020)

USP26 regulates TGF‐β signaling by deubiquitinating and stabilizing SMAD7
por: Kit Leng Lui, Sarah, et al.
Publicado: (2017)

On-Target Anti-TGF-β Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?
por: Teixeira, Adilson Fonseca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_odf5kno3h4429r01bcq6aqne3j